# Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation

> **NCT05743400** · PHASE4 · RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 35 (estimated)

## Conditions studied

- Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy

## Interventions

- **DRUG:** Thymoglobulin 25 milligrams (mg) Injection
- **BIOLOGICAL:** blood test

## Key facts

- **NCT ID:** NCT05743400
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-25
- **Primary completion:** 2025-04-25
- **Final completion:** 2025-04-25
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05743400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05743400, "Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT05743400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*